Treanda (Bendamustine Hydrochloride) – CLL | DengYueMed

Treanda Application Scope

Treanda is an intravenous chemotherapy drug containing bendamustine hydrochloride used to treat blood cancers.

Characteristics

• Ingredients: Bendamustine Hydrochloride

• Properties:

  • Bifunctional mechlorethamine derivative causing DNA cross-links

  • 94–96% protein-bound; metabolized by CYP1A2; half‑life ~40 min

• Packaging Specification:

  • Solution: single-dose vials, 45 mg/0.5 mL or 180 mg/2 mL (90 mg/mL)

  • Lyophilized powder: 25 mg or 100 mg vials, reconstituted to 5 mg/mL

• Storage:

  • Store refrigerated 2–8 °C (36–46 °F)

  • Solution stable at ≤25 °C, excursions to 30 °C allowed

• Expiry Date:

  • As per vial/carton labeling and regulatory approvals (check packaging)

  • Storage expiry is defined on the label

• Executive Standard: Meets FDA-approved label requirements

• Approval Number: FDA NDA 022249

• Date of Revision: Most recent label revision, Nov 2019

• Manufacturer: Originally Cephalon (now Teva Pharmaceuticals USA); generics by Meitheal

Guidelines for the Use of Treanda

• Dosage and Administration:

  • For CLL: 100 mg/m² IV over 30 min on Days 1–2, every 28 days, up to 6 cycles

  • For iNHL: 120 mg/m² IV over 60 min on Days 1–2, every 21 days, up to 8 cycles

  • Dose modifications/delays for Grade 3‑4 hematologic or ≥Grade 2 non‑hematologic toxicity

  • Reduce to 50 mg/m² or 90 mg/m² accordingly

  • Preparation:

    • Reconstitute powder with sterile water

    • Dilute in 0.9% NaCl or 2.5% dextrose before infusion

 

• Adverse Reactions:

  • Common:

    • myelosuppressive (neutropenia, anemia, thrombocytopenia)

    • nausea, vomiting, fever, fatigue, diarrhea, rash, cough

  • Serious: infections, PML, infusion reactions, hepatic toxicity, hypersensitivity/anaphylaxis

• Contraindications:

  • Known hypersensitivity to bendamustine or components (PEG‑400, propylene glycol, mannitol)

  • Severe renal (CrCl <30–40 mL/min) or moderate/severe hepatic impairment

• Precautions:

  • Monitor CBC, platelets, liver, and renal function

  • Avoid use in significant organ impairment

  • Prevent extravasation; wear protective gear during handling

  • Pregnancy/lactation: embryo‑fetal risk; advise contraception and breast‑feeding avoidance

Treanda Interactions

• Drug Interactions:

  Metabolized by CYP1A2; other drug interactions are potential, though not extensively characterized

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
• It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.